| Array BioPharma's ARRY-520 Well Tolerated and Demonstrates Preliminary Activity as a Single Agent in Multiple Myeloma Patients (Business Wire) BOULDER, Colo.----Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein inhibitor, ARRY-520. The data, which were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma. us.rd.yahoo.com |
IPO Market Sizzles - In China The Burrill Report submits: Wondering if the IPO window is open? Well there’s no doubt about it if you are talking about the IPO market in China. The life sciences sector has raised $6.1 billion through initial public offerings in the past 12 months, far outpacing the activity in the United States. And, despite the collapse of Charles River's (CRL) $1.6 billion acquisition of Wuxi (WX), M&A activity is growing.We spoke to Greg Scott, president and founder of the consulting firm ChinaBio and publisher of ChinaBio Today, about the thriving IPO market for life sciences companies there, how that’s evolved over the past year and what the outlook is moving forward.Complete Story » seekingalpha.com |
EpiCept's Ambitious Pipeline Douglas Cress submits:By vandersonCancer and chronic pain are two of the most widespread conditions afflicting humanity today. Developing therapeutics for either one of these targets is daunting enough for any life sciences company. But EpiCept Corporation (Nasdaq: EPCT), a Tarrytown, New York-based pharmaceutical company, is tackling both. Acute myeloid leukemia (AML) is the most common form of leukemia in adults. According to the National Cancer Institute, approximately 12,000 people in the U.S. will be diagnosed with and 9,000 will die from AML in 2010. An estimated 47,000 patients in the European Union currently suffer from AML. Many AML patients are successfully treated with chemotherapy drugs, typically experiencing complete remission. However, the majority (75-80%) of patients will experience a relapse of leukemia, usually within one to two years. There are currently no approved, effective remission therapies for AML in the U.S.Complete Story » seekingalpha.com |
Enzo Biochem 4Q loss widens on costs [AP] - Biotechnology company Enzo Biochem Inc. said Thursday that its fourth-quarter loss widened as it accounted for restructuring costs. us.rd.yahoo.com |
VA Research celebrates 85 years of discovery, innovation, advancement - Video Research Week 2010: Video Highlights 85 Years of Discovery, Innovation, and Advancement feedproxy.google.com |